Xillix develops, manufactures and markets technologies that captures and process images used in the early detection of cancer.
Overview: The company has received preliminary approval from the U.S. Food and Drug Administration of the company's cancer detection devices and made international marketing alliances, making it the hottest small-ap biotech story of the year.
Internet:http://www.xillix.com
Business Highlights:* Received U.S. FDA approval for its auto-florescence bronchoscope to inspect lungs for cancerous tissue for early lung cancer detection. It has already achieved European regulatory approval.
*the company is expanding its marketing pact with Tokyo-based Olympus Optical for granting worldwide distribution and marketing rights to Olympus for its Life-Lung imaging technology. *AccuMed international said it signed a letter of intent to acquire a one-third stake in Xillix's Oncometrics unite.
*The unite has several poducts to launch including a device for automating the Pap smear test for cervical cancer. (SYMBOL-XLX on TSE $4.20 Canadian) |
